News
BioGenes celebrates the launch of its new website! Receive a 5% discount on your online order for polyclonal antisera.
BioGenes is offering a 5% discount on all new polyclonal antibody orders until 31st of July 2013. To claim this offer use the online order form and enter the promotional code 'NW2013' in the section “Further requirements”.
Order online
We truly hope you enjoy exploring our new website. Please feel free to send us any comments or feedback!
BioGenes Receives French Research Tax Credit (CIR) Accreditation
BioGenes would like to announce that it has received CIR accreditation for a three-year period from the French Ministry of Higher Education and Research.
The French research tax credit initiative ('Crédit d'Impôt Recherche', CIR) gives eligible biopharmaceutical or agricultural organizations subject to corporate tax in France the ability to claim tax relief on expenditures generated by subcontracting R&D to BioGenes.
CIR is a tax incentive to stimulate R&D and particularly adapted to the needs of small and medium-sized enterprise. We are delighted to receive this accreditation as it allows our customers in France to benefit from a tax relief of up to 30% of their R&D expenditure committed to BioGenes.
Press Releases
Company is developing pre-optimized HCP assay kits
Berlin, Germany, February 28, 2013 / B3C newswire / - BioGenes GmbH, a global leader in host cell protein (HCP) assay development, announced a strong increase in sales volume in 2012, the year of the company’s 20th anniversary, due to a high demand of specific antibodies and ELISA assays used in drug development processes. In particular, the HCP assay development business showed a remarkable growth increasing by 36% over 2011.
BioGenes is a recognized partner of pharmaceutical companies all over the world. The company has been evaluated by a leading global accounting and auditing firm to be one of the leading companies in HCP assay development.
“Our long-term strategy to focus on HCP assay development pays off and we expect the growth to continue at a similar pace in the months ahead,” said Dagmar Schwertner-Knoll, Marketing Director of BioGenes. “The next milestone is the development of pre-optimized HCP assay kits for more reliable host cell protein detection.”
About BioGenes
BioGenes GmbH specializes in highly sophisticated and customized antibody and immunoassay development and is an experienced and reliable partner for process development improvements in all areas of quality control, diagnostics and drug discovery. BioGenes is certified to meet the international requirements and regularities of quality assurance and animal welfare. The Company maintains long-term relationships with research institutes, universities and biotech and pharmaceutical companies, including eight of the ten largest pharmaceutical companies in the word.
Contact
Dagmar Schwertner-Knoll
Marketing/Sales Director
BioGenes GmbH
+49-30-65762380
d.schwertner@biogenes.de
BioGenes to Develop Specific HCP Assay for Boehringer Ingelheim
Berlin, Germany, June 14, 2012 - BioGenes GmbH, a specialist in immunoassay and sophisticated antibody development, today announced that is has signed a collaboration agreement with Boehringer Ingelheim to develop several product- specific host cell protein (HCP) assays for late stage drug substances.
Proof of HCP depletion during the purification process is an essential part of release testing and the regulatory compliance documentation. HCPs can still be present at significant concentrations even after the last purification step of the drug substance. BioGenes develops highly sensitive HCP assays that can detect HCPs at very low levels.
“BioGenes will provide on-call assay development capacities to both speed up the development and disburden Boehringer Ingelheim’s inhouse capabilities,” said Dr. Alexander Knoll, Managing Director of BioGenes.
Product-specific HCP assays are usually required in clinical phase III studies to demonstrate consistency of manufacturing. In the early process development phase as well as in early clinical phases, generic assays available as off-the shelf kits are usually acceptable.
About BioGenes
BioGenes GmbH specializes in highly sophisticated and customized antibody and immunoassay development and is an experienced and reliable partner for process development improvements in all areas of quality control, diagnostics and drug discovery. BioGenes is certified to meet the international requirements and regularities of quality assurance and animal welfare. The Company maintains long- term relationships with research institutes, universities and biotech and pharmaceutical companies, which include eight of the ten largest pharmaceutical companies in the world.
About Boehringer
IngelheimThe Boehringer Ingelheim group is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 145 affiliates and more than 44,000 employees. In 2011, Boehringer Ingelheim achieved net sales of about 13.2 billion euro. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel medications of high therapeutic value for human and veterinary medicine. Today, Boehringer Ingelheim is one of the world’s leading companies for contract development and manufacture of biopharmaceuticals. All types of services from mammalian cell line or microbial strain development to final drug production can be delivered within a one-stop-shop concept. Boehringer Ingelheim delivers services for pre-clinical development up to global market supply with a strong commitment to its customers at its global manufacturing facilities for mammalian cell culture and microbial fermentation. Boehringer Ingelheim has brought 19 molecules to market and has many years of experience in multiple molecule classes such as monoclonal antibodies, recombinant proteins, interferons, enzymes, fusion molecules and plasmid DNA. Furthermore, high-titer platform technologies for new antibody mimetic formats such as scaffold proteins and antibody fragments are available for the manufacture of customer products.
Contact at Boehringer Ingelheim:
Heidrun Thoma Corporate
Communications Boehringer Ingelheim GmbH
55216 Ingelheim/Germany
Phone: +49/6132 77 3966
Twitter: www.twitter.com/boehringer
More information:
bio-cmo@boehringer-ingelheim.com
Contact at BioGenes:
Dagmar Schwertner
BioGenes GmbH
Koepenicker Str. 325
D-12555 Berlin, Germany
Phone: +49/30 65762380
More information:
www.biogenes.de
Contact
